ACST News and Press, Acasti Pharma Inc. From 04/04/23

Acasti Announces Appointment of Prashant Kohli as CEO PR Newswire LAVAL, QC , April 4, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage specialty pharma company advancing drug candidates for rare and orp...

Acasti Pharma Inc. Announces the Resignation of a Director PR Newswire LAVAL, QC , March 30, 2023 /PRNewswire/ -- Acasti Pharma Inc. (" Acasti " or the " Company ") (NASDAQ: ACST) a late-stage, specialty pharma company advancing three clin...

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange Canada NewsWire Acasti also confirms no exposure to Silicon Valley Bank ("SVB") or Silvergate Bank LAVAL , Québec , March 13, 2...

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference Canada NewsWire LAVAL, QC , March 8, 2023 /CNW/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three ...

Acasti Pharma Recognizes Rare Disease Day Canada NewsWire LAVAL, QC , Feb. 28, 2023 /CNW/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addre...

Acasti Pharma Inc. (ACST) Q3 2023 Earnings Conference Call February 14, 2023 01:00 p.m. ET Company Representatives Jan D'Alvise - President, Chief Executive Officer Brian Ford - Chief Financial Officer Pierre Lemieux - Chief Operating and Scientific Officer, Co-Founder...

Acasti Pharma press release ( NASDAQ: ACST ): Q3 GAAP EPS of -$0.09. The Company finished the second fiscal quarter ended December 31, 2022, with $31.3 million in cash, cash equivalents and short-term investments. Management continues to believe that based on current projectio...

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug ...

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023 PR Newswire Call to be held on Tuesday, February 14th at 1:00 PM Eastern Time LAVAL, QB , Feb. 7, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Comp...

LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces tha...